Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameWuxi Bio
Stock Code02269
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities全球领先的生物制剂服务供应商,向制药及生物技术公司提供全面、综合及高度定制的生物制剂发现、开发及生产服务。
Listing Date2017-06-13
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市外高橋自貿區富特中路288號
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewuxibiologics.com.cn
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 20.60 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering Shares192,982,500 shares
HK Public Offer Shares (Initial)19,298,500 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)173,684,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,134,118,057 shares
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 3,975,439,500

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 168.03B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利约人民币141.1百万元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201420152016
Revenue 331,850557,042989,029
Cost of sales -208,596-376,321-599,919
Gross profit 123,254180,721389,110
Other income and gains, net 12,7536,9177,523
Selling and distribution expenses -4,303-13,447-15,326
Administrative expenses -43,862-72,220-94,606
Operating profit 51,56867,933200,001
Net finance costs -2,556-2,531-24,155
Profit before tax 49,01265,402175,846
Income tax expense -7,034-20,893-34,750
Profit for the year 41,97844,509141,096
Balance Sheet
Item 201420152016
Cash and cash equivalents 5,948158,229169,102
Trade and bills receivables 160,398283,275419,376
Inventories 33,55549,91978,988
Total current assets 229,157601,112829,856
Total assets 636,6701,356,7161,984,996
Total current liabilities 260,8941,201,928800,825
Total liabilities 264,8401,210,7151,714,529
Total equity 371,830146,001270,467
Interest-bearing borrowings 55,410455,8591,129,443
Cash Flow Statement
Item 201420152016
Net cash from operating activities 21,505107,15081,921
Net cash from investing activities -50,120-336,216-421,144
Net cash from financing activities 30,436377,400332,763
Net increase in cash 1,772152,28110,873
Depreciation of PP&E 42,30957,00693,185
Purchase of PP&E -51,044-334,362-428,883
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 28.25
First Day OpenHK$ 25.0
First Day Change37.14%
First Day Volume143609000.0
First Day Turnover3805510000.0
Use of Proceeds
1、約45.1%或1,428.3百萬港元,將用于償還我們全部未清償銀行融資; 2、約44.9%或1,420.3百萬港元,將用于建造新設施及設施改進及維護; 3、約10%或316.5百萬港元,將用于我們的營運資金及其他一般企業用途。

Underwriting Syndicate

Joint Sponsors (3)
Merrill Lynch (Asia Pacific) Limited CE AAC198 Morgan Stanley Asia Limited CE AAD291 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Overall Coordinators (3)
Merrill Lynch (Asia Pacific) Limited CE AAC198 Morgan Stanley Asia Limited CE AAD291 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Bookrunners (3)
Merrill Lynch (Asia Pacific) Limited CE AAC198 Morgan Stanley Asia Limited CE AAD291 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Lead Managers (4)
Merrill Lynch (Asia Pacific) Limited CE AAC198 Morgan Stanley Asia Limited CE AAD291 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 HEAD & SHOULDERS SECURITIES LIMITED CE AFS455

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman李革—
Company Secretary黃躍;岑影文—
No director data available.

Major Shareholders

Major Shareholders & Holdings控股股东为李革博士、赵博士、张朝晖先生、刘晓钟先生(一致行动),合计持股约80.59%;Biologics Holdings直接持股约75.43%。
About this page

This page shows Wuxi Bio (02269) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect